Can I Take Quercetin with Repatha (Evolocumab)?

Why This Combination Raises Questions

Patients prescribed Repatha for familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD) often take dietary supplements. A 2022 NHANES analysis found that 57.6% of U.S. Adults on a statin or other lipid-lowering drug reported concurrent supplement use [1]. Quercetin ranks among the most popular flavonoid supplements, with annual U.S. Sales exceeding $200 million, according to the American Botanical Council [2].

Where the Concern Originates

The interaction flag traces to quercetin's documented inhibition of cytochrome P450 enzymes, specifically CYP3A4 and CYP2C9, in liver microsome studies [3]. Many drug interaction databases flag CYP3A4 inhibitors broadly. Because evolocumab is sometimes grouped alongside small-molecule cholesterol drugs in these databases, the alert can appear even though monoclonal antibodies bypass CYP metabolism entirely.

Why the Flag Is Misleading for Evolocumab

Evolocumab is a 144 kDa immunoglobulin. It is cleared through target-mediated disposition (binding to circulating PCSK9) and non-specific proteolysis in the reticuloendothelial system [4]. The Repatha prescribing information lists no CYP-mediated drug interactions [5]. This means quercetin's CYP3A4 inhibition is pharmacokinetically irrelevant to evolocumab clearance.

How Evolocumab Works and Why CYP Enzymes Do Not Apply

Evolocumab binds circulating PCSK9 protein, preventing it from degrading LDL receptors on hepatocyte surfaces. With more LDL receptors available, the liver clears more LDL-C from the bloodstream. In the FOURIER trial (N=27,564), evolocumab 140 mg every two weeks reduced LDL-C by 59% versus placebo and lowered the composite cardiovascular endpoint by 15% (HR 0.85, 95% CI 0.79 to 0.92) over a median 2.2 years [6].

Monoclonal Antibody Clearance Pathway

All therapeutic monoclonal antibodies, including evolocumab, are degraded into amino acids through intracellular proteolytic catabolism [4]. They do not pass through hepatic phase I or phase II metabolism. The FDA's 2020 guidance on drug interaction studies for therapeutic proteins confirms that standard CYP-based interaction studies are generally not required for monoclonal antibodies [7].

Practical Implication

Because evolocumab never encounters CYP3A4 in its elimination pathway, even a potent CYP3A4 inhibitor would not alter its serum concentration. Quercetin's in vitro Ki for CYP3A4 ranges from 1.1 to 16.4 µM depending on the substrate [3], but this value is irrelevant when the co-administered drug is a biologic.

How Quercetin Affects Lipids Independently

Quercetin (3,3',4',5,7-pentahydroxyflavone) has shown modest lipid-lowering effects in human studies. A meta-analysis of 9 RCTs (N=590) published in Critical Reviews in Food Science and Nutrition found that quercetin supplementation at doses of 100 to 1,000 mg/day significantly reduced total cholesterol by 4.76 mg/dL and LDL-C by 4.52 mg/dL compared to placebo [8].

Quercetin's Proposed Mechanism on PCSK9

Animal data from a 2020 study in the Journal of Nutritional Biochemistry showed quercetin reduced hepatic PCSK9 mRNA expression by approximately 40% in high-fat-diet-fed mice [9]. If this mechanism operates in humans, quercetin could theoretically complement evolocumab's effect on the same pathway. However, no human trial has tested this combination specifically.

Antioxidant and Anti-Inflammatory Properties

Quercetin also reduces oxidized LDL (ox-LDL), a key driver of atherogenesis. A randomized crossover trial (N=93) published in the Journal of Nutrition found that 150 mg/day of quercetin lowered systolic blood pressure by 2.6 mmHg and reduced plasma ox-LDL concentrations in overweight subjects with a high cardiovascular risk phenotype [10]. These effects are pharmacodynamically additive to, not conflicting with, evolocumab's LDL receptor upregulation.

Pharmacokinetic Interaction Analysis

A proper interaction assessment evaluates absorption, distribution, metabolism, and excretion (ADME) overlap between the two compounds.

Absorption

Evolocumab is administered subcutaneously and absorbed through the lymphatic system, reaching peak serum concentration (Tmax) in 3 to 4 days [5]. Quercetin is absorbed orally in the small intestine with a bioavailability of approximately 2% for the aglycone form and up to 17% for glycoside conjugates [11]. The two absorption pathways do not intersect.

Distribution and Protein Binding

Quercetin is approximately 99% protein-bound in plasma, primarily to albumin [11]. Evolocumab distributes into blood volume with an estimated volume of distribution of 3.3 L at steady state [5]. Monoclonal antibodies do not compete for albumin binding sites. No displacement interaction is expected.

Metabolism

This is the critical point of analysis. Quercetin undergoes extensive phase II conjugation (glucuronidation, sulfation, methylation) in the gut wall and liver, primarily via UGT1A1, UGT1A3, SULT1A1, and COMT [12]. It also inhibits CYP3A4, CYP2C9, and CYP1A2 in vitro [3]. Evolocumab, as detailed above, undergoes proteolytic catabolism and has no CYP involvement [4]. No metabolic intersection exists.

Excretion

Quercetin metabolites are excreted renally and through bile with a plasma half-life of 11 to 28 hours [11]. Evolocumab has an effective half-life of 11 to 17 days and is cleared through PCSK9-mediated and nonspecific proteolysis [5]. The elimination routes are entirely separate.

Pharmacodynamic Considerations

While the pharmacokinetic interaction risk is negligible, pharmacodynamic overlap deserves a brief assessment.

Additive LDL Lowering

Both quercetin and evolocumab reduce LDL-C, though through different magnitudes and mechanisms. Evolocumab lowers LDL-C by approximately 60% [6], while quercetin's effect is roughly 5 to 10 mg/dL in most trials [8]. The combined effect could be mildly additive. This is not a safety concern. There is no "floor" below which LDL-C becomes dangerous in clinical trial data. The FOURIER trial included patients who achieved LDL-C levels below 20 mg/dL without excess adverse events [13].

Antiplatelet Activity

Quercetin demonstrates mild antiplatelet effects in vitro through inhibition of collagen-stimulated platelet aggregation [14]. Patients on evolocumab who also take aspirin or clopidogrel should mention quercetin use, though no bleeding events attributable to quercetin supplementation have been reported in clinical trials.

Histamine and Mast Cell Effects

Quercetin stabilizes mast cells and reduces histamine release, which accounts for its popularity as a "natural antihistamine" [15]. This property has no known interaction with PCSK9 inhibitors. If anything, the anti-inflammatory effect of mast cell stabilization could theoretically support vascular health in patients with ASCVD.

Monitoring Recommendations

Even in the absence of a documented interaction, responsible co-administration requires a monitoring plan.

Lipid Panel Schedule

Continue lipid testing per your prescriber's schedule, typically at 4 to 12 weeks after starting evolocumab and then every 3 to 12 months [16]. If you add quercetin, consider requesting a lipid panel 4 to 6 weeks after starting the supplement to document any additional LDL-C reduction.

Liver Function

Quercetin at typical supplement doses (500 to 1,000 mg/day) has not been associated with hepatotoxicity in clinical trials lasting up to 12 weeks [8]. Evolocumab does not require routine liver function testing per its FDA label [5]. Routine hepatic monitoring is unnecessary for this combination unless you are also taking a statin or have baseline liver disease.

What to Report to Your Prescriber

Tell your doctor about quercetin use. This allows accurate interpretation of lipid panel trends. Report any unusual bruising or bleeding if you are co-administering anticoagulants or antiplatelet agents. Report any injection-site reactions, new muscle pain, or cognitive symptoms, as these relate to evolocumab rather than to quercetin.

Dose and Timing Guidance

No dose-separation window is needed for this combination. The pharmacokinetic pathways are entirely independent. Quercetin is typically taken at 500 mg once or twice daily with meals to improve absorption [11]. Evolocumab is injected every two weeks (140 mg) or monthly (420 mg) [5].

Choosing a Quercetin Product

Quality varies significantly among quercetin supplements. A 2019 analysis of commercially available quercetin products found that 22% contained less than 80% of the labeled dose [17]. Select products that carry a USP Verified, NSF Certified for Sport, or ConsumerLab-approved seal.

Dose Ceiling

The European Food Safety Authority (EFSA) has established that quercetin intakes up to 500 mg/day as a supplement show no safety concern [18]. Doses above 1,000 mg/day have limited safety data. Stay at or below 1,000 mg/day unless supervised by a physician.

Populations Requiring Extra Caution

Patients on Warfarin or Other Anticoagulants

Quercetin inhibits CYP2C9, the primary enzyme responsible for (S)-warfarin metabolism [3]. Patients on warfarin who add quercetin should have INR checked within 1 to 2 weeks of starting supplementation. This caution relates to the quercetin-warfarin interaction, not to evolocumab.

Patients on Cyclosporine

Quercetin may increase cyclosporine levels by inhibiting CYP3A4 and intestinal P-glycoprotein [3]. Transplant recipients on evolocumab and cyclosporine should consult their transplant pharmacist before adding quercetin.

Pregnant or Lactating Patients

Evolocumab is FDA pregnancy category not assigned (monoclonal antibodies cross the placenta in the second and third trimesters) [5]. Quercetin lacks adequate human pregnancy safety data [18]. Neither should be used in pregnancy without direct physician supervision.

What the Guidelines Say About Supplements and PCSK9 Inhibitors

The 2018 AHA/ACC Multisociety Cholesterol Guideline recommends against using supplements as substitutes for proven lipid-lowering therapy [16]. The guideline does not, however, prohibit concurrent supplement use provided the patient maintains adherence to prescribed therapy. The Endocrine Society's 2020 clinical practice guideline on lipid management in endocrine disorders similarly emphasizes that supplements should not replace pharmacotherapy in high-risk patients [19].

The key message: quercetin is not a substitute for evolocumab in patients with FH or established ASCVD. It may be a reasonable adjunct if the patient understands its modest effect size and continues prescribed therapy without interruption.